The main goal of this study was to analyse whether initial addition of glucocorticoid to DMARD therapy influences the long-term course of the disease in patients with early rheumatoid arthritis. All patients from the Swiss RA cohort SCQM with recent-onset arthritis (disease duration ≤1 year) were analysed. The exposure of interest was the use of glucocorticoids (GCs) at baseline. As primary outcome, we considered clinical and radiographic disease progression, assessed by the disease activity (disease activity score, DAS-28), function (health assessment questionnaire disability index, HAQ-DI) and structural joint damage (Ratingen erosion score). The baseline disease characteristics were compared using standard descriptive statistics. The effects of initial GC use on disease progression during follow-up were Key message: The use of GC in early arthritis may compensate unfavourable prognostic factors.
Significance and innovation
• GC use may have a beneficial role in patients with unfavourable prognostic factors.
-Patients with initial GC treatment had more unfavourable prognostic factors than those without.
-Early-RA patients with and without initial GC use demonstrated similar clinical and radiographic development during follow-up.
• In our opinion, in the absence of contraindications, GCs should always be considered as bridging therapy in early disease and used, in particular, if unfavourable prognostic factors are present.
estimated using linear mixed models with random slope and random intercept, adjusted for potential confounders. In total, 592 patients with early disease were available, with 4.3 years of follow-up (average). Of these, 363 were initially treated with glucocorticoids (GC patients) and 228 were not (no-GC patients). DAS-28 (4.6 vs. 4.3, p = 0.01) and the HAQ-DI (0.94 vs. 0.82, p = 0.01) were higher at baseline in GC patients, while other prognostic factors were balanced at baseline. Neither the change of DAS-28, of HAQ-DI nor of the development of joint erosions differed between the two groups during follow-up. Escalation of treatment employing biologics was documented in 18.0% of the no-GC patients and 27.3% of the GC patients (p < 0.01). In this cohort, patients with early RA initially treated with GCs had higher measures of disease activity at baseline in comparison to no-GC patients. Despite a similar course of the disease in GC versus non-GC patients, the higher escalation rate to biologic agents
Introduction
Glucocorticoids (GC) have anti-inflammatory and diseasemodifying properties in RA patients [1] [2] [3] . GC treatment added to disease-modifying antirheumatic drug (DMARD) therapy is successful at low (<10 mg/day) [4] [5] [6] and at higher doses [7, 8] . Higher doses of GCs lead to a more rapid shortterm clinical improvement in comparison to patients not treated with GCs at all [7] . In the COBRA-light study, a reduced glucocorticoid dose was equally effective as higher GC doses employed in the classical COBRA regimen [9] . Whether the significantly better outcomes in clinical trials using combinations of synthetic DMARDs plus GCs versus DMARD monotherapy might be at least in part due to the GC component [6] [7] [8] is under discussion. This hypothesis is supported by studies showing that adding GC to DMARD monotherapy [4, 5] is beneficial.
It is well known that long-or even intermediate-term use of GCs can lead to adverse events [10] . The European League Against Rheumatism (EULAR) task force, therefore, recommends that GCs should be tapered as rapidly as possible [11] .
The primary objective of this study was to analyse whether initial corticosteroid therapy influences the course of early disease in RA patients. A secondary objective of this study was to compare baseline characteristics of early-arthritis patients with or without initial GC use, possibly explaining the rheumatologist's decision to add GCs.
Methods

Study population and design
The Swiss Clinical Quality Management (SCQM) in rheumatoid arthritis is a RA national cohort study performed by office-or hospital-based rheumatologists, which has been described in detail elsewhere [12, 13] . SCQM has obtained a Swiss-wide ethical approval to collect patient data and a broad consent to perform clinical research related to its aims. In this study, we restricted our analysis to patients with early RA. The analysis includes data collected between January 1998 and November 2011. Inclusion criteria for the analysis were a diagnosis of RA by a rheumatologist and early disease, as defined as less than 367 days from the first symptoms (as reported by the patient). Patients treated with GCs and synthetic or biological DMARDs for more than 31 days before the first visit were excluded from the analysis. Exclusion criteria were missing 28 joint counts at baseline or the absence of follow-up visits, as published before [14, 15] .
Exposure of interest
The primary objective of the study was to analyse whether initial GC therapy influences the course of the disease in early-RA patients.
Outcome parameters
The primary endpoint was the change of disease activity score (DAS)-28 scores. Secondary endpoints were changes in radiographic joint damage and patient-centred outcomes. The patient-centred outcome was assessed using the Stanford Health Assessment Questionnaire (health assessment questionnaire disability index (HAQ-DI)) [16] . Radiographic damage was analysed on serial radiographs according to the number and the size of bone erosions. Erosions were measured prospectively using a validated scoring system (Ratingen score) [17] , based on the amount of joint-surface destruction for each joint. The inter-observer agreement and test-retest reliability were high, as published [17] .
To predict, at baseline, the GC use after 2 years, as a secondary endpoint, all RA patients were separated into two groups depending on the documented GC use after 2 years (defined as long-term use of GCs). The two groups were reanalysed for differences in baseline characteristics.
Statistical analysis
The baseline disease characteristics of patients in the two groups were compared using standard descriptive statistics. Continuous variables were compared using a Student's t test, categorical variables with Χ 2 test. Curves showing changes in DAS-28 and HAQ-DI scores over time were created using loess smoothing of the raw data. The effect of initial GC use on DAS-28 and HAQ-DI scores was estimated using linear mixed models with random slope and random intercept, and adjusted for various baseline factors in a univariate fashion, as well as in a multivariate fashion considering baseline DAS-28 (or HAQ-DI), Ratingen score and ESR. We also examined whether GC initiation was influenced by baseline parameters, ACR/EULAR classification score, rheumatoid factor, DAS-28, anti-citrullinated protein antibodies (ACPA), ESR, age, gender or calendar year of inclusion, in a propensity score analysis using multiple logistic regression. A propensity score was then computed as the predicted log-odds of receiving GCs at baseline and included as a univariate predictor in the linear mixed models described above. All statistical analyses were two-sided at the 0.05 significance level. The analyses were performed using GraphPad Prism 5 software and the lme4 package in R.
Ethics approval
Ethics approval for the collection of patient data for the SCQM cohort was given by the regional review boards. Informed consent was obtained from all patients before inclusion in the SCQM cohort.
Results
Patients
Of the 9627 patients in the database, 756 patients had early RA with a symptom duration of less than 367 days. Six hundred nine patients of these had at least one follow-up in the database, and 592 patients in the database had valid 28 joint counts. The median follow-up for these 592 patients was 44 months (range 0-178), representing a total of 3845 visits.
Baseline demographical data
Patients were categorized into two groups: patients treated with GCs (GC patients, n = 363) and not treated with GC (no-GC patients, n = 228) at baseline. Analysis of the demographical data revealed no significant differences in age, gender, disease duration and time of follow-up between the two patient groups, as shown in Table 1 . In two patients, new treatment was initiated within the period of 31 days prior to baseline. Exclusion of these patients did not influence data analysis (not shown). Disease activity was higher at the inclusion visit in GC patients. In detail, mean DAS-28 was 4.6 in GC patients vs. 4.3 in no-GC patients (p = 0.011). Similarly, the ESR was also higher in GC patients (mean 30.5 vs. 24.3 mm/h, resp., p = 0.0013), whereas CRP (mean 23.7 GC vs. 15.8 no GC, p = 0.13), swollen (7.9 vs. 7.1, p = 0.09) and tender (8.0 vs. 7.6, p = 0.48) joint counts and erosion scores at disease onset showed no statistically significant differences. ACPA and rheumatoid factors also did not differ between the two patient groups. The average HAQ-DI was higher in GC (0.94) than in no-GC patients (0.82, p = 0.0122, Table 1 ).
The average GC dose in the GC patients was 14.0 mg/day (±9.28) at baseline (median 10 mg/day). The range was from1.25 to 60 mg/day (Fig. 1 ).
Clinical and radiographic progression
Disease activity, patient-reported outcome and development of joint erosions were similar in both patient groups during follow-up, as demonstrated by DAS-28, HAQ-DI and erosion scores (Fig. 2) . The time of follow-up between the two patient groups did not differ (mean 171.2 months GC vs. 186.9 months no GC, p = 0.0529).
To find out whether GCs were preferentially started in more severe cases of RA, we analysed if GC initiation was associated with the baseline parameters (rheumatoid factor, DAS-28, ACPA, ESR, age, gender and calendar year) in a propensity score analysis using logistic regression (not shown). After adjusting for this propensity score, no statistically significant difference in clinical activity (difference in DAS-28 0.04 on average, p = 0.67) or radiographic disease progression (erosion score 0.75 higher in GC patients, p = 0.29) was observed in patients with and without the use of GCs. The same was true for the patient-oriented outcome (HAQ-DI 0.03 higher in GC patients, p = 0.47). The results were similar when using a propensity score from the best-fit model, which included only age and baseline ESR.
Drug survival of initial GCs and new initiation of GCs during follow-up
The drug survival of GCs after start at baseline was analysed. GC treatment was stopped in 301 patients during follow-up, after a median of 680 days. In parallel, GC treatment was initiated in 48 of the initial no-GC patients after an average of 662 days (Fig. 3a) . Thus, GC treatment was continued in 47.2% of the initial GC patients and started in 21.9% after 2 years of follow-up of the initial no-GC patients (not statistically significant).
Conventional synthetic DMARD treatment
Treatment with conventional synthetic DMARDs was initiated preferentially with methotrexate (MTX) in both treatment groups. MTX was a part of the initial therapeutic strategy in 75.5% of the GC patients and 66.9% of the no-GC patients (Χ 2 test 4.492,1, p = 0.03, Table 2 ). The average initial MTX doses were 14.4 and 14.1 mg/week in the GC and no-GC patients, respectively (data not shown). In parallel, the first therapeutic modification (independent of whether the MTX dose was modified in patients already treated with MTX or whether MTX was initiated) was more frequent in GC patients (23.4% in GC vs. 4.7% in no-GC patients, Χ 2 test 38.32,1, p < 0.0001). There were no significant differences comparing GC and no-GC patients for the use of sulfasalazine, antimalarials and leflunomide (data not shown).
Escalation to biologics
Escalation of treatment with biologic agents occurred in 18.0% of the no-GC patients after 909 days on average and in 27.3% of the GC patients after 754 days (Χ 2 test for the number of patients requiring biologics 6.96, p = 0.0097, time to first biologic p = 0.31, Fig. 3b ). 
Co-morbidities
Analysis of the number and kind of co-morbidities in our cohort of early-RA patients did not reveal differences between the two patient groups, neither at baseline nor during followup (Table 3) .
Predictors for GC use after 2 years
To explore which baseline parameters were associated with long-term GC treatment, we examined patients still on GC after 2 years (Table 4) . Patients with long-term GC use over 2 years had an increased HAQ-DI of 1.05 at baseline, as compared to 0.86 in those not treated with GCs after 2 years (p = 0.005), but no other differences were found for the different demographical and serological parameters indicative of disease activity or joint destruction.
Discussion
In this study, we analysed the effect of initial GC treatment as an adjunct to DMARD therapy in a cohort of 592 RA patients with early disease. Patients treated with GCs had higher objective and subjective disease activities at the first visit, as measured by the DAS-28 and HAQ-DI, respectively. These differences evened out during follow-up. These results may help to shed light on two frequently debated questions:
& Is the decision for initial treatment with GCs triggered by unfavourable prognostic factors? & Is GC use from first clinical visit onward in early RA necessary to modify the further course of the disease?
Is the decision for initial treatment with GCs triggered by unfavourable prognostic factors?
In our study, disease activity (ESR, DAS-28) was higher and functional limitations (HAQ-DI) were more pronounced in patients initially treated with GCs than in those who were not. The most likely explanation is that rheumatologists tended to add concomitant GC preferentially to their patients with more severe RA, which is corroborated by the fact that these patients also received more frequently biologic antirheumatic agents during follow-up than non-GC users. It is well known that long-term GC treatment is associated with many adverse events. As a consequence, rheumatologists try to taper and eventually stop GCs. The reasons for maintaining GC treatment for an extended period of time should be well founded, and GCs should only be used because of a therapeutic necessity in the individual patient. In our study, 20-50% of the patients No-GC patients initially treated with glucocorticoids, GC patients initially treated without glucocorticoids, MTX methotrexate, SSZ sulfasalazine, Lef leflunomide, HCQ hydroxychloroquine were still treated with GCs after 2 years (Fig. 3a) . The HAQ-DI at baseline was the only parameter significantly higher in patients on GCs after 2 years. The patient's individual perception of disease-associated limitations affecting functionality in daily life, thus, correlated with the use for GCs after 2 years. Another explanation for initial use of GCs could be the application of predefined therapeutic concepts including the use of GCs in all early-RA cases by individual rheumatologists or centres. However, we could not demonstrate an association between the initial use of GCs and individual rheumatologists or centres involved (data not shown), suggesting that GC use was no related to a strong physician bias as in a natural study.
Is the GC use from first clinical visit onward in early RA necessary to modify the further course of the disease?
In view of the loss of the initial differences in disease activity during follow-up, our data suggest-at first sight-that the initial use of GCs does not improve long-term results.
No differences between patients initially treated or not with GCs in radiographic progression, DAS-28 or HAQ-DI could be found. However, biologic agents were more frequently initiated during follow-up in GC than in no-GC patients, most probably reflecting an initial clinical disease state less responsive to therapy in these patients. GC may only be necessary in patients with higher baseline DAS and HAQ-DI scores.
A considerable number of clinical studies [18] have demonstrated that more aggressive treatment may lead to better results [19] . Increased baseline parameters such as ESR, high joint counts as part of the DAS-28 and HAQ-DI are known to have a negative influence on the course of RA [20, 21] . These parameters were higher in the GC group [22] of our cohort, indicating a potential for more aggressive disease. Considering the equal course of disease in the two patient groups, GCs may actually have prevented a more severe course of the disease. The E U L A R g u i d e l i n e s r e c o m m e n d t h a t Bl o w -d o s e Cardiological n = 5 n = 2 Dermatological n = 18 n = 7 Gastrointestinal n = 24 n = 16
General n = 2 n = 4
Haematological n = 1 n = 3 Hepatical n = 1 -Ears, nose, through n = 2 n = 2
glucocorticoids^should ideally be considered Bas part of the initial treatment strategy^since addition of GCs to DMARD therapy as Bbridging therapy^has been shown to have a similar effect as the addition of a TNF antagonist to MTX [11, [23] [24] [25] . In view of the multitude of parameters involved, data derived from clinical cohorts are never unequivocal. Our analysis, however, may support the use of GC in early RA in patients with higher clinical disease measures such as higher DAS-28, ESR and HAQ-DI (high DAS-28, ESR and HAQ-DI [20, 21] ). This conclusion is similar to the statement in the EULAR guidelines in phase II for the therapeutic decision after the first DMARD has failed [11] . These recommendations propose a second synthetical DMARD in patients with favourable prognostic factors and a first biologic agent in those with unfavourable prognostic factors.
Health economic considerations
The percentage of 27% GC and 15% no-GC patients requiring a step-up of therapy to a biologic agent appeared rather low. would be equivalent to overall savings of CHF 94,265 (in 100 patients). Or, in other words, the costs would be equivalent if 178 early-RA patients are treated continuously with prednisolone over 1 year to one patient requiring therapeutic escalation to a biologic agent. These considerations are, as a matter of course, purely economic and do not take into account costs caused by therapyrelated side effects of either corticosteroids or biologics.
Limitation
GCs are frequently associated with adverse events (AEs). Assessment of AEs is certainly an issue for the analysis of cohort data. We have analysed the adverse event rate in both groups and found no differences between the two groups (data not shown). The relative risk for comorbidity was 1.12 comparing GC and no-GC patients. This leads to a number needed to harm (NNH) of 1960.1. However, the r a t e o f A E s w a s v e r y l o w a n d w e t h i n k t h a t underreporting of AEs is a major bias to this analysis. The initial glucocorticoid doses employed in the GC patients varied from 1.25 to 60 mg/day at onset of treatment. The improved effect of higher initial GC doses has been reviewed by Laan et al. [27] . However, it cannot be derived from the database whether the physicians coded the initiated GC dose or, rather, the dose reached after initial tapering. Therefore, no conclusions can be drawn from our data on the initial GC dose used and its effect on the course of the disease.
Summary and conclusions
Patients with initial GC treatment had more unfavourable prognostic factors than those without, implying a more aggressive evolution of their disease. However, early-RA patients with and without initial GC use demonstrated similar clinical and radiographic evolution, suggesting that initial GC use may have had a beneficial role in these patients with unfavourable prognostic factors. In our opinion, in the absence of contraindications, GCs should be considered as bridging therapy in early disease in particular, if prognostic factors of severe disease are present.
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